Family offices and allocators
Farmland is hard to allocate to because two properties in different countries are rarely described on the same basis. Phoeniks scores parcels through the same model ensemble and the same evidence levels worldwide, which makes cross-border comparison defensible rather than anecdotal.
- 7 / 29
- 21
- 9
- Per-parcel estimate, confidence band, audit trail
What allocators get#
- A single comparable score across geographies and crops, with confidence bands.
- Institutional data feed for portfolio monitoring rather than one-off lookups.
- Disclosure inputs aligned to SFDR and PCAF reporting requirements.
- Provenance on every input, for the investment committee file.
Frequently asked
- Do you give investment advice?
- No. Phoeniks produces evidence and scores. Allocation decisions and their suitability remain entirely with the investor.
Related pages
Banks and lenders
Per-parcel yield evidence for agricultural credit files: collateral defensibility, portfolio concentration and model-risk documentation lenders can file.
Reinsurers and insurers
Tail behaviour, spatial covariance and calibration evidence for crop and parametric portfolios, delivered as an actuarial validation pack.
Brokers and land agencies
Substantiate a farmland listing with modelled yield potential, environmental overlays and an exportable diligence pack buyers can review.
Farmland buyers
Assess a farmland parcel before the site visit: modelled yield, crop fit, environmental constraints and a shared pre-diligence room.
Auditors and verification bodies
Reproducible model runs, source provenance and evidence levels for external auditors and verification bodies reviewing agricultural claims.
Portfolio managers
Portfolio-level yield trajectories, physical-risk concentration and disclosure inputs for managers holding farmland or agricultural credit.
Development finance institutions
Regional production and climate-exposure evidence for development banks and blended-finance programmes in data-sparse markets.
See also
Request access
Institutional access. No self-serve trial.